Media & Resources

Partners in five countries will discover and develop monoclonal antibodies to treat critical illness from snake venom, which harms nearly 3 million people each year.

Phase I Trial to Evaluate Safety and Immunogenicity of Engineered Envelope Protein.

David L. Blumberg, Jim Connolly, John Nkengasong, John Shiver, Anne Simonds, and Rajeev Venkayya join IAVI Board in 4Q 2018.

Collaboration to develop optimal combination of HIV-specific antibodies and ensure that cost is not a barrier to access.

Phase I trial to evaluate safety and immunogenicity of vaccine candidate engineered to elicit targeted immune response against HIV.

Data from two Phase II clinical trials conducted by Aeras and partners indicate promise for future of TB vaccine development.

IAVI to apply expertise in viral vector vaccines to Lassa Fever prevention effort.

Adel A. F. Mahmoud, MD, PhD, was a member of the IAVI Board of Directors from 2012. He was an important advocate for a global focus on vaccine development and equitable access, including the importance of advancing HIV R&D.